Flumatinib (HHGV678) is an orally bioavailable antineoplastic tyrosine kinase inhibitor. Flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. Flumatinib was extensively metabolized after oral administration, and the major metabolic pathways observed were amide hydrolysis, demethylation, oxidation, and glucuronide conjugation. It is in phase III clinical trials for the treatment of Chronic myeloid leukemia (in China).

INCB9471 is a non-competitive, potent and selective CCR5 small-molecule antagonist patented by pharmaceutical company Incyte Corporation for treatment of human immunodeficiency virus infection. INCB9471 potently inhibited macrophage inflammatory protein-1beta-induced monocyte migration and infection of peripheral blood mononuclear cells by a panel of R5-HIV-1 strains. INCB9471 was shown to be safe and highly efficacious in reducing HIV viral load in phase I and II human clinical trials

Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) originally extracted from a tropical tree (Calophyllum lanigerum) in the Malaysian rain forest. Viral life-cycle studies indicate that calanolide A acts early in the infection process, similar to the known HIV reverse transcriptase (RT) inhibitor 2', 3'-dideoxycytidine. In enzyme inhibition assays, calanolide A potently and selectively inhibits recombinant HIV type 1 RT but not cellular DNA polymerases or HIV type 2 RT within the concentration range tested. Phase I studies have found that calanolide A is well tolerated. Consequently, it has potential clinical applications in combination with other antiviral drugs to suppress HIV-1 mutants. Nevertheless, the development of calanolide A has been delayed due to its low therapeutic index (range: 16–279), non-ideal antiviral activity, and the complexity of its extraction from plants

Anacor Pharmaceuticals (now Pfizer) was developing AN-2898, a boron-containing, small-molecule inhibitor of type 4 cyclic nucleotide phosphodiesterase (phosphodiesterase IV), as a topically applied therapy for psoriasis and atopic dermatitis. AN-2898 inhibits the release of tumore necrosis factor-alfa (TNFα), interleukin (IL)-12, and IL-23. AN-2898 also inhibits the activity of phosphodiesterase (PDE) 4 and 7. AN-2898 IC50 values for inhibition of PDE4 and PDE7 activity is 0.06 and 0.21 uM, respectively. AN-2898 is a competitive, reversible inhibitor of PDE4 with a Ki of 65 nM. AN-2898 has been studied in clinical trials for atopic dermatitis and psoriasis. The development of AN-2898 appears to have been discontinued.

S-Hydroprene is an insecticide used against cockroaches, beetles, and moths. S- Hydroprene belongs to the class of insecticides known as insect growth regulators. S-Hydroprene disrupts normal development and molting of insects by mimicking hormones produced by immature insects. S-Hydroprene causes different effects on different insects. It may cause adult sterility, physical body changes, water loss, and premature death. S-hydroprene is currently used indoors, and therefore are not expected to pose a risk to the environment.

Temiverine was developed as an antimuscarinic and calcium-antagonist agent for the treatment of overactive bladder. Temiverine participated in clinical trials; however, the development of the drug was discontinued on the pre-registration stage.

Potassium cation K-42 is a radioactive tracer. It was used to study K exchanges across the myocardial cell wall and measuring uptake of isotope by the myocardium, to measure of potassium ion influx in Chinese hamster ovary (CHO) cells and other researches related to K-transport in vivo and in vitro.

Primaperone is substituted amino ketone patented by Science-Union et Cie.-Societe Francaise de Recherche Medicale as hypotensive and tranquilizing agents. Primaperone acts as serotonin receptor antagonis and demonstrate activity in behavioral despair test